Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis.

Schopman JE, Simon AC, Hoefnagel SJ, Hoekstra JB, Scholten RJ, Holleman F.

Diabetes Metab Res Rev. 2014 Jan;30(1):11-22. doi: 10.1002/dmrr.2470. Review.

PMID:
24030920
2.

[The efficacy and safety of linagliptin in elderly patients with type 2 diabetes: a pooled analysis of eight placebo-controlled clinical trials].

Guo XH, Feng ZK, Xu LH.

Zhonghua Nei Ke Za Zhi. 2017 Aug 1;56(8):588-594. doi: 10.3760/cma.j.issn.0578-1426.2017.08.007. Chinese.

PMID:
28789492
3.

Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis.

Hirst JA, Farmer AJ, Dyar A, Lung TW, Stevens RJ.

Diabetologia. 2013 May;56(5):973-84. doi: 10.1007/s00125-013-2856-6. Epub 2013 Mar 15. Review.

4.

Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.

Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A.

BMJ. 2012 Mar 12;344:e1369. doi: 10.1136/bmj.e1369.

PMID:
22411919
5.

Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents.

Chan SP, Colagiuri S.

Diabetes Res Clin Pract. 2015 Oct;110(1):75-81. doi: 10.1016/j.diabres.2015.07.002. Epub 2015 Jul 9. Review.

PMID:
26361859
6.
7.
8.

Incidence of and risk factors for severe hypoglycaemia in treated type 2 diabetes mellitus patients in the UK--a nested case-control analysis.

Bruderer SG, Bodmer M, Jick SS, Bader G, Schlienger RG, Meier CR.

Diabetes Obes Metab. 2014 Sep;16(9):801-11. doi: 10.1111/dom.12282. Epub 2014 Mar 19.

PMID:
24612200
9.

Comparison of efficacy, secondary failure rate, and complications of sulfonylureas.

Harrower AD.

J Diabetes Complications. 1994 Oct-Dec;8(4):201-3. Review.

PMID:
7833494
10.

Severe hypoglycaemia the "tip of the iceberg": an underestimated risk in both type 1 and type 2 diabetic patients.

Halimi S.

Diabetes Metab. 2015 Apr;41(2):105-6. doi: 10.1016/j.diabet.2015.01.005. Epub 2015 Mar 29. No abstract available.

PMID:
25824635
11.

Risk of hypoglycaemia in people aged ≥65 years receiving linagliptin: pooled data from 1489 individuals with type 2 diabetes mellitus.

Nauck M, Araki A, Hehnke U, Plat A, Clark D, Khunti K.

Int J Clin Pract. 2018 Oct;72(10):e13240. doi: 10.1111/ijcp.13240. Review.

PMID:
30216648
12.

Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.

Lo C, Jun M, Badve SV, Pilmore H, White SL, Hawley C, Cass A, Perkovic V, Zoungas S.

Cochrane Database Syst Rev. 2017 Feb 27;2:CD009966. doi: 10.1002/14651858.CD009966.pub2. Review.

PMID:
28238223
13.

Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study).

Ahn CH, Han KA, Yu JM, Nam JY, Ahn KJ, Oh TK, Lee HW, Lee DH, Kim J, Chung CH, Park TS, Kim BJ, Park SW, Park HK, Lee KJ, Kim SW, Park JH, Ko KP, Kim CH, Lee H, Jang HC, Park KS.

Diabetes Obes Metab. 2017 May;19(5):635-643. doi: 10.1111/dom.12866. Epub 2017 Feb 17.

PMID:
28026912
14.

Drug-induced severe hypoglycaemia in Type 2 diabetic patients aged 80 years or older.

Greco D, Angileri G.

Diabetes Nutr Metab. 2004 Feb;17(1):23-6.

PMID:
15163121
15.

A meta-analysis of the hypoglycaemic risk in randomized controlled trials with sulphonylureas in patients with type 2 diabetes.

Monami M, Dicembrini I, Kundisova L, Zannoni S, Nreu B, Mannucci E.

Diabetes Obes Metab. 2014 Sep;16(9):833-40. doi: 10.1111/dom.12287. Epub 2014 Apr 10.

PMID:
24635837
16.

The benefits and risks of DPP4-inhibitors vs. sulfonylureas for patients with type 2 diabetes: accumulated evidence from randomised controlled trial.

Zhou JB, Bai L, Wang Y, Yang JK.

Int J Clin Pract. 2016 Feb;70(2):132-41. doi: 10.1111/ijcp.12761. Epub 2015 Dec 28. Review.

PMID:
26709610
17.

Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide.

Holstein A, Plaschke A, Egberts EH.

Diabetes Metab Res Rev. 2001 Nov-Dec;17(6):467-73.

PMID:
11757083
18.

Severe hypoglycaemia in elderly patients with type 2 diabetes and coexistence of cardiovascular history.

Piątkiewicz P, Buraczewska-Leszczyńska B, Kuczerowski R, Bernat-Karpińska M, Rabijewski M, Kowrach M.

Kardiol Pol. 2016;74(8):779-785. doi: 10.5603/KP.a2016.0043. Epub 2016 Apr 4.

19.

Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: a pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials.

Owens DR, Traylor L, Dain MP, Landgraf W.

Diabetes Res Clin Pract. 2014 Nov;106(2):264-74. doi: 10.1016/j.diabres.2014.08.003. Epub 2014 Aug 12.

20.

Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials.

Zhang Y, Hong J, Chi J, Gu W, Ning G, Wang W.

Diabetes Metab Res Rev. 2014 Mar;30(3):241-56. doi: 10.1002/dmrr.2482. Review.

PMID:
24123720

Supplemental Content

Support Center